HIV-1 Eradication: Early Trials (and Tribulations)
2015; Elsevier BV; Volume: 22; Issue: 1 Linguagem: Inglês
10.1016/j.molmed.2015.11.004
ISSN1471-499X
AutoresAdam M. Spivak, Vicente Planelles,
Tópico(s)HIV/AIDS Research and Interventions
ResumoAntiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with access to treatment. However, ART does not lead to viral eradication owing to the persistence of replication-competent, unexpressed proviruses in long-lived cellular reservoirs. The potential for long-term drug toxicities and the lack of access to ART for most people living with HIV-1 infection have fueled scientific interest in understanding the nature of this latent reservoir. Exploration of HIV-1 persistence at the cellular and molecular level in resting memory CD4(+) T cells, the predominant viral reservoir in patients on ART, has uncovered potential strategies to reverse latency. We review recent advances in pharmacologically based 'shock and kill' HIV-1 eradication strategies, including comparative analysis of early clinical trials.
Referência(s)